
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific demonstrated robust financial performance in Q4, with significant revenue growth across multiple segments, including a 35% year-over-year organic increase in Electrophysiology and a 16.1% growth in Cardiovascular revenues. The company reported a gross margin of 70.7%, surpassing consensus expectations and indicating improved product mix despite some tariff impacts. With consistent growth trends anticipated in the Electrophysiology market and an overall company growth expectation that exceeds peers, Boston Scientific is well-positioned for continued success in the competitive medical device sector.
Bears say
Boston Scientific experienced a decline in its operating margin, down 10 basis points year-over-year, attributed to increased research and development expenses despite a slight gross margin improvement. Organic growth rates have decelerated, falling from 15.3% in the third quarter of 2025 to 12.7% in the fourth quarter, primarily due to declining demand for the FARAPULSE system amid rising competition and slowing adoption rates for pulse field ablation technology. The company’s 2026 sales growth guidance of 10.5-11.5% is below prior consensus expectations, indicating potential challenges in meeting market forecasts and raising concerns about the company’s operational traction and overall financial performance.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares